TABLE 4.
Clinical outcomes
| Outcomea | Rejected (n = 67) | Accepted (n = 34) | P value |
|---|---|---|---|
| DDD per 1,000 patient-days (median [range]) | 0.668 (0.01–11.5) | 0.224 (0.002–1.93) | <0.001 |
| DOT per 1,000 patient-days (median [range]) | 0.764 (0.11–9.19) | 0.417 (0.03–2.63) | <0.001 |
| Length of stay (median [range]) (days) | 39 (4–599) | 26 (6–173) | 0.112 |
| Hospitalization charges (median [range]) | $17,470 ($1,704–273,356) | $10,843 ($2,556–116,839) | 0.088 |
| 30-day readmission (no. [%])b | 29 (52) | 13 (38) | 0.212 |
| Infection related | 7 (13) | 3 (9) | 0.737 |
| 30-day mortality (no. [%]) | 10 (15) | 0 (0) | 0.015 |
| Infection related | 4 (6) | 0 (0) | 0.297 |
| Clinical improvement 7 days after initial review (no. [%]) | 52 (78) | 29 (85) | 0.360 |
| Clinical improvement at end of carbapenem therapy (no. [%]) | 58 (87) | 31 (91) | 0.746 |
| Microbiologic clearance 7 days after 1st positive culture(no. [%]) | 14 (70) | 11 (85) | 0.431 |
| Carbapenem-resistant organism within 30 days of start of carbapenem therapy (no. [%]) | 2 (3)c | 0 (0) | 0.549 |
a
DDD, daily defined doses; DOT, days of therapy.
b
Excluded in-hospitalization mortality.
c
Organisms identified were Stenotrophomonas maltophilia and Acinetobacter spp. from blood cultures.